Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes.

Carew JF, Kooby DA, Halterman MW, Kim SH, Federoff HJ, Fong Y.

Mol Ther. 2001 Sep;4(3):250-6.

2.

Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.

Zager JS, Delman KA, Malhotra S, Ebright MI, Bennett JJ, Kates T, Halterman M, Federoff H, Fong Y.

Mol Med. 2001 Aug;7(8):561-8.

3.
4.

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Todo T.

Front Biosci. 2008 Jan 1;13:2060-4. Review.

PMID:
17981691
5.

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.

Wong RJ, Patel SG, Kim S, DeMatteo RP, Malhotra S, Bennett JJ, St-Louis M, Shah JP, Johnson PA, Fong Y.

Hum Gene Ther. 2001 Feb 10;12(3):253-65.

PMID:
11177562
6.

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.

Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC, Molnar-Kimber KL.

Cancer Gene Ther. 2000 Feb;7(2):275-83.

7.

Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.

Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y.

Gene Ther. 2006 Apr;13(8):705-14.

PMID:
16421599
8.

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL.

Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9.

9.
10.

Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.

Ishida D, Nawa A, Tanino T, Goshima F, Luo CH, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Tsurumi T, Nishiyama Y, Kikkawa F.

Cancer Lett. 2010 Feb 1;288(1):17-27. doi: 10.1016/j.canlet.2009.06.014. Epub 2009 Jul 14.

PMID:
19604626
11.

Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer.

Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H, Fong Y.

Cancer Gene Ther. 2002 Nov;9(11):935-45.

12.

Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.

Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y.

Cancer Gene Ther. 2002 Apr;9(4):356-64.

14.

Targeted oncolytic herpes simplex viruses for aggressive cancers.

Wong J, Lee C, Zhang K, Rennie PS, Jia W.

Curr Pharm Biotechnol. 2012 Jul;13(9):1786-94. Review.

PMID:
21740360
15.

Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.

Kim SH, Wong RJ, Kooby DA, Carew JF, Adusumilli PS, Patel SG, Shah JP, Fong Y.

Eur J Cancer. 2005 Jan;41(2):313-22.

PMID:
15661558
16.

Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.

Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D'Angelica M, Fong Y.

Surgery. 2007 Apr;141(4):520-9. Epub 2007 Feb 14.

17.

In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors.

D'Angelica M, Karpoff H, Halterman M, Ellis J, Klimstra D, Edelstein D, Brownlee M, Federoff H, Fong Y.

Cancer Immunol Immunother. 1999 Jan;47(5):265-71.

PMID:
10022470
18.

Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.

Lin SF, Gao SP, Price DL, Li S, Chou TC, Singh P, Huang YY, Fong Y, Wong RJ.

Clin Cancer Res. 2008 Mar 1;14(5):1519-28. doi: 10.1158/1078-0432.CCR-07-4628.

19.

Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207.

Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T.

Jpn J Cancer Res. 2000 Dec;91(12):1339-44.

PMID:
11123435
20.

Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.

Nakano K, Todo T, Zhao G, Yamaguchi K, Kuroki S, Cohen JB, Glorioso JC, Tanaka M.

J Gene Med. 2005 May;7(5):638-48.

PMID:
15754306

Supplemental Content

Support Center